Introduction

Crohn’s disease is a long‑term inflammation of the digestive tract that tends to flare and settle. This page compares care when Crohn’s starts in childhood versus adulthood.

Crohn’s affects people of all ages, with incidence peaking in adolescence and early adulthood.^1, Care priorities differ by age at diagnosis: childhood focuses on growth, puberty and bone health, while comorbidities and cumulative inflammation shape adult diagnoses.²

At a glance: what’s the same and what differs

Quick comparison

How clinicians define paediatric‑onset and adult‑onset Crohn’s

Clinics and studies typically categorise Crohn’s disease by age at diagnosis using the Paris classification, which impacts growth monitoring and surveillance timing.

• Paediatric‑onset: before age seventeen (with sub‑groups such as very‑early‑onset under six, early-onset between the ages of six and ten, and adolescent between ten and seventeen) because genetics, presentation and growth considerations vary across these ranges 
• Adult‑onset: age seventeen or older,  “late‑onset” is sometimes used for diagnoses after about fifty, as comorbidities shape management³

These labels help tailor growth monitoring, transition planning and surveillance schedules, but do not alone predict individual severity.

Core differences across a lifetime

Growth, puberty and bone health (paediatric‑onset)

When Crohn’s begins in childhood, persistent gut inflammation and reduced absorption can limit height gain, delay puberty and weaken bones. Corticosteroids can further reduce bone mineral density. Care typically includes tracking height velocity, assessing pubertal development, optimising dietary intake and arranging bone density assessment when indicated.² Even when adult height is achieved, people diagnosed in childhood have a higher lifetime risk of low vitamin D, iron and vitamin B12. Supplementation is common, particularly after ileal disease or resection.^2,9,11

Disease behaviour and surgery

Paediatric‑onset Crohn’s more often presents with extensive gut involvement and earlier complications. This historically raised the likelihood of surgery by young adulthood, though contemporary cohorts show this risk is falling with earlier effective therapy. Adult‑onset disease tends to progress more slowly. When surgery is necessary, it typically occurs later, with fewer resections and less downstream malabsorption.⁷

Induction and maintenance treatment: what diverges and what aligns

Induction

In children and young people, exclusive enteral nutrition (EEN), a medically supervised, formula-only diet taken by mouth or via a feeding tube for about six to eight weeks, is recommended as the first‑line treatment for inflammation in the gut lining (luminal Crohn’s) to induce remission and avoid steroid effects on growth and bone. If EEN is not feasible, short courses of corticosteroids (anti‑inflammatory tablets) are used.² Diet‑led options, such as the Crohn’s disease exclusion diet, a structured diet that removes specific foods, plus partial enteral nutrition, may also help in research settings.^12,13,14

In adults, induction typically uses systemic corticosteroids (for example, prednisolone).⁵ Budesonide is a gut‑targeted steroid used short‑term for mild to moderate ileocaecal Crohn’s, affecting the terminal ileum (end of the small bowel) and the caecum (first part of the colon). It helps settle inflammation with fewer whole‑body effects than prednisolone. It is usually limited to short courses up to eight weeks, is not suitable for extensive colitis, stricturing (narrowing) or fistulising (abnormal tunnels) disease, and is not used for maintenance. High‑risk presentations may start an early biologic.^5,16

Maintenance

Long-term control usually relies on immunomodulators (tablets such as azathioprine or methotrexate that dampen immune activity) and biologics (antibody therapies that block specific inflammatory signals). Care is planned around a treat-to-target approach in which steroid-free remission is the aim. 

Targets typically include settled symptoms, normalised blood and stool markers (for example, CRP and faecal calprotectin), and healing of the bowel lining on endoscopy. In paediatric patients with high‑risk features such as growth failure, deep ulcers, extensive colitis, or penetrating/perianal complications, guidelines support earlier biologic therapy, often anti‑TNF with an immunomodulator, to optimise durability. 

Adults follow step‑up or early biologic strategies based on risk and prior exposure. Small‑molecule options in selected adults include JAK inhibitors ( janus kinase inhibitors) and S1P modulators – tablet medicines that target immune signals. S1P drugs keep certain white blood cells out of the gut. Key safety considerations include infections (including herpes zoster) and, specifically for JAK inhibitors, warnings about venous thromboembolism and major cardiovascular events. A vaccination review and risk assessment are recommended.⁵

Cancer surveillance and the role of duration

Colorectal cancer (CRC)  surveillance is relevant to colonic Crohn’s disease (Crohn’s colitis). Small‑bowel‑only Crohn’s follows different logic and does not require routine CRC surveillance. Where the colon is involved, intervals are typically one to five years based on individual risk (extent and activity of colitis, bile‑duct condition like primary sclerosing cholangitis, family history).^4,10

The risk of bowel cancer rises with the duration of colonic inflammation, not just age, so surveillance is anchored to years since colitis onset. As a guide, surveillance colonoscopy is started about eight to ten years after the onset of colonic inflammatory bowel disease (IBD), then repeated at risk‑stratified intervals. For paediatric‑onset Crohn’s with colonic involvement, that timetable begins earlier in life.¹⁵

Mental health and lived experience

Growing up with hospital visits, procedures and dietary limitations can affect confidence, schooling and social life. Adolescents with IBD have higher rates of anxiety and depression and benefit from planned psychological support. Adults diagnosed later may grieve the loss of a previously symptom‑free period but can draw on established routines and support. Structured transition models improve preparedness and continuity.

Day‑to‑day management in adulthood

Follow‑up in adulthood is similar regardless of age at onset, and plans are tailored to symptoms, surgical history and goals.¹⁷

Maintenance therapy

In ongoing care, biologic medicines are commonly used. Some are given by subcutaneous injection every two to eight weeks (for example, adalimumab, ustekinumab, risankizumab), while others are intravenous infusions roughly every eight weeks (for example, infliximab, vedolizumab). They are often paired with an immunomodulator to sustain response and limit anti‑drug antibodies.⁵

Routine labs and stool tests

Monitoring usually includes periodic full blood count, liver enzymes and inflammatory markers, alongside faecal calprotectin (a stool protein that reflects gut inflammation) to track disease activity between endoscopies.⁸

When to do therapeutic drug monitoring (TDM)

Therapeutic drug monitoring (blood tests that measure drug levels and antibodies) is used when indicated. Typical triggers include loss of response, a post‑induction check, or proactive assessments set out in local protocols, with results guiding dose optimisation or switching.

Nutrition support

Nutrition often remains part of long‑term care. Iron, vitamin B12 and vitamin D/calcium are frequently required, especially after ileal resection or with steroid exposure. Bile‑acid binders can help in diarrhoea attributable to ileal disease or resection.

Symptom control

Pragmatic measures such as antidiarrhoeals and antispasmodics are used for day‑to‑day symptoms. Short courses of corticosteroids are generally reserved for early flares under a pre‑agreed plan with the IBD team.⁵

Vaccination and infection awareness

While on immunosuppression, vaccination schedules typically emphasise non‑live vaccines and avoidance of live vaccines. Services also encourage prompt medical review for fever, chest symptoms, severe abdominal pain or sustained bleeding.

Smoking cessation

Across studies, smoking is linked with higher Crohn’s activity and post‑operative recurrence, whereas cessation is associated with fewer flares and a lower risk of surgery. Programmes usually combine behavioural support with pharmacotherapy.^1,5

Transition from paediatric to adult care

For people diagnosed in childhood, moving to adult services is a defined phase, and a planned handover prevents gaps.

A structured handover from paediatric gastroenterology to an adult IBD service supports continuity and self‑management. You should receive a written summary of diagnosis, operations and medication history. The team should set out surveillance schedules and arrange referrals to dietetics, bone health checks and mental health support. Parents and carers can help a young person take the lead in appointments, request repeats and recognise red‑flag symptoms.⁵

How partners, parents and friends can help

• Learn the treatment schedule and plan around infusion or injection days 
• Normalise practicalities such as seating near exits and planning toilet access 
• Offer help with school or work letters during flares or surveillance weeks 
• Attend key appointments if invited, to help track questions and decisions 

FAQs

Does paediatric‑onset Crohn’s always mean a worse outcome?

Not necessarily. It often means more intensive care earlier, with closer attention to growth, bones and nutrition. With modern treatments, many people diagnosed in childhood achieve long periods of remission, complete education and work, and live full adult lives.²

Will I need surgery?

Some people will, at some point. Early surgery is more common in paediatric‑onset Crohn’s because of longer exposure time, but rates are falling with effective therapy. Surgery can improve quality of life when directed at strictures or fistulas, and appropriate medical therapy afterwards reduces recurrence.

Are the medicines different for adults who had Crohn’s as children?

Largely no. In adulthood, the medicine list looks similar across both groups; differences mainly reflect prior exposures, resection history and absorption issues.

When should cancer surveillance start?

Surveillance is tied to how long the colon has been inflamed, plus individual risk factors. Many people begin regular colonoscopy about eight to ten years after the onset of colonic disease.⁴

Summary

• In adulthood, maintenance treatment and monitoring are broadly similar whether Crohn’s began in childhood or later, guided by phenotype and risk 
• Paediatric‑onset disease needs extra attention to growth, puberty, bone health and early nutrition, and carries a higher chance of surgery by young adulthood, although contemporary data show declining paediatric surgery rates 
• Cancer surveillance is tied to the duration of colonic inflammation, so it starts earlier for those whose disease began earlier
• Good outcomes depend on consistent maintenance therapy, planned surveillance, attention to nutrition and bone health, and timely mental health support 
• A structured transition from paediatric to adult care helps you stay in control of appointments, medicines and warning signs